Bantham. I think you are annoyed you did not invest when the shares18 Jan 2024 16:21
Were around 10p just before xmass.
Mr Newland did not say exactly what you posted.
You said "he was quite specific that Eisai would pay at the top end of the range which in itself was one of the most extraordinary things i have ever heard from a CEO )". He did not say that exectly. He said "Eisai Inc.have got 80 active oncology clinical trials with 60,000 participants". He reminded us that the tests would usually be "before, during and after" the teatment. This does not mean that they are going to use angle for all these. He was just painting a picture of the potential market of 60,000 x 3 = 180,000 tests. He then said Angle charge up to $5000 per test. Minimum $1,000. He commented "with Eisai we are at the top end". However this is open to interpretation. The "top end" could mean specifically $5000, or more likely IMHO between $3500 and $5000. That is good! Very good.
All IMHO.